GSK Gets OTC Mevacor U.S. Marketing Rights In Agreement With Merck
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline will have exclusive U.S. marketing rights for what would be a first nonprescription statin, pending FDA approval of Merck's Rx-to-OTC switch application for its Mevacor cholesterol-lowering drug